Document is current
Any future updates will be listed below
-
Authors
Berenson, James R. https://orcid.org/0000-0003-1587-6104
Limon, Andrea
Rice, Stephanie
Safaie, Tahmineh
Boccia, Ralph
Yang, Honghao
Moezi, Mehdi
Lim, Stephen
Schwartz, Gary
Eshaghian, Shahrooz
Brobeck, Matthew
Swift, Regina
Eades, Benjamin M.
Bujarski, Sean
Sebhat, Yohana
Ray, Rudra
Kim, Susanna
Del Dosso, Ashley
Vescio, Robert
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03110822 at ClinicalTrials.govDocuments that mention this clinical trial
A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone
https://doi.org/10.1007/s11523-024-01049-w
-
Funding
Funding for this research was provided by:
Incyte
- License Information
-
More Information
Article History
Accepted: 4 March 2024
First Online: 20 April 2024
Declarations
:
: This study was supported by Incyte Corporation (Gaithersburg, MD, USA) through providing the drug ruxolitinib for this study.
: James R. Berenson received research funding from Incyte Corporation to conduct the clinical trial, holds equity and receives compensation from ONCOtracker, and receives speaker fees and research grant support from Amgen, Bristol Myers Squibb, Incyte Corporation, Janssen, Karyopharm, and Sanofi. Andrea Limon, Stephanie Rice, Tahmineh Safaie, Ralph Boccia, Honghao Yang, Mehdi Moezi, Stephen Lim, Gary Schwartz, Shahrooz Eshaghian, Matthew Brobeck, Regina Swift, Benjamin M. Eades, Sean Bujarski, Yohana Sebhat, Rudra Ray, Susanna Kim, Ashley Del Dosso, and Robert Vescio have no conflicts of interest that are directly relevant to the content of this article.
: This study was approved by an institutional review board (approval number: MOD00586804) on 19 February, 2020.
: All patients included in this study provided informed consent in accordance with local institutional review board requirements and the Declaration of Helsinki.
: Not applicable.
: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
: Not applicable.
: JRB: conceptualization, methodology, formal analysis, investigation, resources, writing - original draft, writing - review and editing, supervision, project administration, funding acquisition; AL: data curation, project administration, investigation; SR: data curation, project administration, investigation; TS: data curation, investigation; RB: investigation, resources; HY: investigation, resources; MM: investigation, resources; SL: investigation, resources; GS: investigation, resources; SE: investigation, resources; MB: project administration, supervision; RS: investigation; BME: investigation; SB: formal analysis, data curation, writing - review; YS: investigation, data management, data curation; RR: investigation, data management, data curation; SK: writing - review and editing; ADD: writing - original draft, writing - review and editing and RV: investigation, resources.
